|C3052||Mouse B7-H3-CHO-K1 Stable Cell Line||2 vials||$2000||Order|
|Cell Line Name||Mouse B7-H3-CHO-K1 Stable Cell Line|
|Host Cell||Adherent CHO-K1|
|Quantity||Two vials of frozen cells (2x106 per vial)|
|Culture Medium||DMEM with 10% FBS, 4 μg/ml puromycin|
|Freezing Medium||90% FBS and 10% DMSO|
|Storage||Liquid nitrogen upon receipt|
|Product Datasheet:||Download PDF|
Detection of mouse B7-H3 expression on mouse B7-H3-CHO-K1 stable cells using a PE-anti-mouse B7-H3 antibody (BioLegend, #124507)
B7-H3, also known as CD276, is a cell surface protein that belongs to the B7 family of immune regulatory molecules. B7-H3 has two isoforms determined by its extracellular domain. In mice, the extracellular domain consists of a single pair of immunoglobulin variable (IgV)-like and immunoglobulin constant (IgC)-like domains, whereas in humans it consists of one pair (2Ig-B7-H3) or two identical pairs (4Ig-B7-H3) due to exon duplication. B7-H3 mRNA is expressed in most normal tissues. Flow cytometric analysis demonstrated inducible expression of B7H3 on monocytes, dendritic cells, and T cells after stimulation with selected cytokines and mitogens.B7-H3 protein is expressed at high frequency on many different cancer types (60% of all cancers).B7-H3 has both costimulatory and coinhibitory properties that can affect the proliferation of CD4+ and CD8+ T cells, production of cytokines, and activity of T cells and NK cells depending on the microenvironment. B7-H3 also exhibits nonimmunological pro-tumorigenic functions such as migration and invasion, apoptosis, cell viability and chemoresistance.
Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2:269-274. 2001.
Zhou WT, Jin WL. B7-H3/CD276: An Emerging Cancer Immunotherapy. Front Immunol. 12:701006. 2021.
Picarda E, Ohaegbulam KC, Zang X. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clin Cancer Res. 22:3425-3431. 2016.